Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.
Richard W. Joseph(Daiichi Sankyo (United States)), Richard Kefford(Broad Institute), David C. Turner, Jeroen Elassaiss‐Schaap(Merck & Co., Inc., Rahway, NJ, USA (United States)), Omid Hamid(Cedars-Sinai Medical Center), Kellie Ann Celentano(Merck & Co., Inc., Rahway, NJ, USA (United States)), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Kapil Mayawala(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dinesh P. de Alwis(Merck & Co., Inc., Rahway, NJ, USA (United States)), Manash Chatterjee(Merck & Co., Inc., Rahway, NJ, USA (United States)), Antoni Ribas(University of California, Los Angeles), Reinhard Dummer(University Hospital of Zurich), Caroline Robert(Institut Gustave Roussy), Xiaoyun Li(Nanjing University), Janice M. Mehnert(NYU Langone Health), Tara C. Gangadhar(University of Pennsylvania), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jill A. Lindia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Adil Daud(University of California, San Francisco)
Cited by 6
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k